RT Journal Article
SR Electronic
T1 A Randomised Clinical Trial of the Safety and Pharmacokinetics of VRC07-523LS Administered via Different Routes and Doses (HVTN 127/HPTN 087)
JF medRxiv
FD Cold Spring Harbor Laboratory Press
SP 2024.01.10.23299799
DO 10.1101/2024.01.10.23299799
A1 Walsh, Stephen R.
A1 Gay, Cynthia L.
A1 Karuna, Shelly T.
A1 Hyrien, Ollivier
A1 Skalland, Timothy
A1 Mayer, Kenneth H.
A1 Sobieszczyk, Magdalena E.
A1 Baden, Lindsey R.
A1 Goepfert, Paul A.
A1 del Rio, Carlos
A1 Pantaleo, Guiseppe
A1 Andrew, Philip
A1 Karg, Carissa
A1 He, Zonglin
A1 Lu, Helen
A1 Paez, Carmen A.
A1 Baumblatt, Jane A. G.
A1 Polakowski, Laura L.
A1 Chege, Wairimu
A1 Janto, Sophie
A1 Han, Xue
A1 Huang, Yunda
A1 Dumond, Julie
A1 Ackerman, Margaret E.
A1 McDermott, Adrian B.
A1 Flach, Britta
A1 Piwowar-Manning, Estelle
A1 Seaton, Kelly
A1 Tomaras, Georgia D.
A1 Montefiori, David C.
A1 Gama, Lucio
A1 Mascola, John R.
A1 HVTN 127/HPTN 087 Study Team
YR 2024
UL http://medrxiv.org/content/early/2024/01/11/2024.01.10.23299799.abstract
AB Background Broadly neutralizing antibodies (bnAbs) are a promising approach for HIV-1 prevention. In the only bnAb HIV prevention efficacy studies to date, the Antibody Mediated Prevention (AMP) trials, a CD4-binding site targeting bnAb, VRC01, administered intravenously (IV), demonstrated 75% prevention efficacy against highly neutralization-sensitive viruses but was ineffective against less sensitive viruses. Greater efficacy is required before passively administered bnAbs become a viable option for HIV prevention; furthermore subcutaneous (SC) or intramuscular (IM) administration may be preferred. VRC07-523LS is a next-generation bnAb targeting the CD4-binding site and was engineered for increased neutralization breadth and half-life.Methods Participants were recruited between 02 February 2018 and 09 October 2018. 124 healthy participants without HIV were randomized to receive five VRC07-523LS administrations via IV (T1: 2.5 mg/kg, T2: 5 mg/kg, T3: 20 mg/kg), SC (T4: 2.5 mg/kg, T5: 5 mg/kg) or IM (T6: 2.5 mg/kg or P6: placebo) routes at four-month intervals. Safety data were collected for 144 weeks following the first administration. VRC07-523LS serum concentrations were measured by ELISA after the first dose through Day 112 in all participants and by binding antibody multiplex assay (BAMA) thereafter in 60 participants (10 per treatment group) through Day 784. Compartmental population pharmacokinetic (PK) analyses were conducted to evaluate the VRC07-523LS serum pharmacokinetics. Neutralization activity was measured in a TZM-bl assay and anti-drug antibodies (ADA) were assayed using a tiered bridging assay testing strategy.Results Injections were well-tolerated, with mild pain or tenderness reported commonly in the SC and IM groups, and mild to moderate erythema or induration reported commonly in the SC groups. Infusions were generally well-tolerated, with infusion reactions reported in 3 of 20 participants in the 20 mg/kg IV group. Peak geometric mean (GM) concentrations (95% confidence intervals) following the first administration were 29.0 μg/mL (25.2, 33.4), 58.5 μg/mL (49.4, 69.3), and 257.2 μg/mL (127.5, 518.9) in T1-T3 with IV dosing; 10.8 μg/mL (8.8, 13.3) and 22.8 μg/mL (20.1, 25.9) in T4-T5 with SC dosing; and 16.4 μg/mL (14.7, 18.2) in T6 with IM dosing. Trough GM concentrations immediately prior to the second administration were 3.4 μg/mL (2.5, 4.6), 6.5 μg/mL (5.6, 7.5), and 27.2 μg/mL (23.9, 31.0) with IV dosing; 0.97 μg/mL (0.65, 1.4) and 3.1 μg/mL (2.2, 4.3) with SC dosing, and 2.6 μg/mL (2.05, 3.31) with IM dosing. Peak VRC07-523LS serum concentrations increased linearly with the administered dose. At a given dose, peak and trough concentrations, as well as serum neutralization titres, were highest in the IV groups, reflecting the lower bioavailability following SC and IM administration. A single participant was found to have low titre ADA at a lone timepoint. VRC07-523LS has an estimated mean half-life of 42 days (95% CI: 40.5, 43.5), approximately twice as long as VRC01.Conclusions VRC07-523LS was safe and well-tolerated across a range of doses and routes and is a promising long-acting bnAb for inclusion in HIV-1 prevention regimens.Competing Interest StatementSRW has conducted clinical trials funded by Janssen Vaccines, Moderna, Pfizer, Vir, Worcester HIV Vaccine, and Sanofi Pasteur, and serves on Independent Data Monitoring Committees for Janssen Vaccines and BioNTech SRW?s spouse is an employee of Regeneron Pharmaceuticals and may hold stock and/or stock options. CLG has received research support from Gilead and ViiV Healthcare and conducted clinical trials funded by Moderna and Novavax. MEA has received research support from Janssen, Be Bio, and Moderna.Clinical TrialNCT03387150Funding StatementUS National Institutes of Health (NIH) [www.nih.gov] grants UM1 AI068614 (STK, CK, CAP, SJ, GDT), UM1 AI068635 (OH, ZH, HL, YH), UM1 AI068618 (KS, GDT, DCM), UM1 AI069412 (SRW, LRB), UL1 RR025758 (LRB), P30 AI50410 (CLG), UM1 AI069423 (CLG), UM1 AI068619 (PA, JD), UM1 AI068617 (TS), UM1 AI068613 (EPM), UM1 TR004406 (CLG). JAGB, LLP, and WC are/were Medical Officers with the National Institute of Allergy and Infectious Diseases (NIAID)/NIH and ABM, BF, LG, and JCM are/were Staff Scientists with NIAID/NIH. The funder had no other role in the study design, data collection and analysis, decision to publish, or preparation of the manuscript.Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:The Partners Human Research Committee of Brigham and Women's Hospital gave ethical approval of this work. The Centre Hospitalier Universitaire Vaudois Institutional Review Board of the Centre Hospitalier Universitaire Vaudois gave ethical approval of this work. The Fred Hutchinson Cancer Research Center Institutional Review Board gave ethical approval of this work done at the University of North Carolina at Chapel Hill, the Ponce de Leon/Emory University, and the University of Alabama at Birmingham. The Fenway Health Institutional Review Board of the Fenway Institute gave ethical approval of this work.I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable.YesUpon acceptance, the data underlying the findings of this manuscript will be made publicly available at the public-facing HVTN website (https://atlas.scharp.org/).